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Increased mRNA encoding for transforming factor-a in C04+ cells
from patients with IgA nephropathy. IgA nephropathy (IgAN) is a
mesangial proliferative glomerulonephritis characterized by predominant
mesangial IgA deposits. Recently, transforming growth factor-/3 (TGF-J3)
is shown to exert widespread effects on extracellular matrix by enhancing
its accumulation. In an experimental model of acute mesangial glomeru-
lonephritis TGF-/3 appeared to be involved in the process of glomerulo-
sclerosis, and treatment with antagonists of TGF-/3 prevented the
development of glomerulosclerosis. We examined the TGF-/3 mRNA
expression by mitogen activated CD4+ T cells from 31 patients with
IgAN, 25 healthy controls and 10 patients with minimal change nephrop-
athy (MCN) or focal glomerulonephritis (FGN) who were comparable in
age and sex. The cytokine gene was analyzed with reverse transcription
followed by polymerase chain reaction and was semiquantitated by
normalizing the differences occurring during reverse transcription and
polymerase chain reaction using a housekeeping gene, 13-actin. CD4+ T
cells from IgA nephritic patients expressed a higher level of TGF-p
mRNA than that of healthy controls or that of MCNIFGN [TGF-13/actin
ratio 1.11 (median), range 0.24 to 3.87 vs. 0.88, range 0.2 to 3.83, P
0.0157 and 0.36 range 0.09 to 1.6, P = 0.006]. When the biopsies were
classified into three grades according to the severity of glomerular and
interstitial pathology, there were highly significant differences between the
TGF-13 mRNA in CD4+ T cells from the three groups of IgA nephritic
patients (grade 1, 0.52, range 0.24 to 0.79; grade 2, 1.2, range 0.5 to 3.33;
grade 3, 2.17, range 1.45 to 3.87]. Furthermore, immunofluorescent
reactivity of anti-TGF-3 antibody in the mesangium was associated with
the severity of histopathologic grading (P < 0.05). Our data suggest that,
in addition to the local synthesis of TGF-13 by mesangial cells, there is
increased TGF-13 gene expression in circulating CD4+ T cells that may
also contribute to the glomerulosclerosis in IgA nephropathy.
IgA nephropathy (IgAN) is the most common glomerulone-
phritis worldwide [1] and an important cause of end-stage renal
failure [2]. The pathology is characterized by a mesangial prolif-
erative glomerulonephritis with predominant mesangial IgA de-
posits. Superimposed glomerular lesions of focal and segmental
lobular tuft necrosis can be found in focal proliferative and diffuse
mesangial proliferative lesions. There are more significant in-
creases of glomerular sclerosis and crescent formation in diffuse
mesangial cell proliferation than in focal glomerulonephritis,
indicating that the severity of diffuse mesangial cell hyperplasia is
the most important prognostic factor in IgAN [3}. Both glomer-
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ular and interstitial sclerosis are important prognostic factors in
the subsequent development of renal impairment [4,5].
Recently, transforming growth factor-n [TGF-13] is shown to
exert widespread effects on extracellular matrix by enhancing its
accumulation. In an experimental model of acute mesangial
glomerulonephritis, TGF-13 appeared to be involved in the pro-
cess of glomerular sclerosis and treatment with antagonists of
TGF-/3 prevented the development of glomerular sclerosis [6]. In
the present study, we examined the TGF-f3 mRNA expression by
mitogen activated CD4+ T cells from patients with IgAN and
correlated the levels of TGF-13 mRNA expression with the
severity of glomerular and interstitial pathology. Our data suggest
there is increased TGF-J3 gene expression in CD4+ T cells that
may enhance the glomerular sclerosis in IgA nephropathy.
Methods
Patients
Thirty-one Chinese patients (13 males and 18 females) with a
clinical and renal immunopathological diagnosis of primary IgAN
were studied. They had been symptomatic for 12 months or more,
with proteinuria ranging from 0.3 to 4.9 g/day, and were between
19 and 62 years of age (mean SD, 32.1 7.8 years). IgAN was
diagnosed by the presence of predominant granular IgA deposits,
mainly in the glomerular mesangium and occasionally along the
peripheral capillary basement membrane in immunofluorescence
studies, as well as mesangial electron-dense deposits in ultrastruc-
tural examination. None of these patients received corticosteroid
or cytotoxic treatment. The light microscopic features of the
biopsy material were examined blindly without clinical details to
evaluate the glomerular and interstitial changes, which were
classified into grades 1 to 3 in increasing severity according to a
modified classification described previously [7]. Grade 1 denoted
the presence of mild mesangial proliferation (cell, matrix or both)
with no interstitial changes. Grade 2 indicated moderate degree
of mesangial proliferation and increase in matrix, occasional areas
of glomerulosclerosis and crescent formation (in <20% of the
glomeruli) and 5 to 15% of interstitial changes. Grade 3 denoted
the presence of Grade 2 findings but with more than 30%
glomerulosclerosis and >15% interstitial changes. Systemic lupus
esythematosus, Henoch-Schönlein purpura, and hepatic diseases
were excluded by detailed clinical history, examination, and
negative laboratory tests for hypocomplementemia, anti-DNA
antibody, or hepatitis B virus surface antigen. No significant renal
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impairment was documented in these patients and their endoge-
nous creatinine clearance were greater than 70 ml/min/1.73 m2.
Blood samples were collected from each patient at clinical
quiescence (no macroscopic hematuria and urinary erythrocyte
count <10,000/mi in uncentrifuged urine). The period between
renal biopsy and measurement of TGF-/3 gene expression in
CD4+ T cells ranged from 2 to 30 months. None of the patients
had increased serum creatinine exceeding 15% of the pre-biopsy
values within the 12 months prior to the measurement of TGF-p
gene expression.
Controls
Twenty-five healthy Chinese subjects (12 males and 13 females)
with normal renal function were used as healthy controls and
disease controls included eight patients with minimal change
nephropathy (MCN) and two patients with focal glomerulone-
phritis (FGN). No microscopic hematuria or proteinuria was
documented in the healthy control subjects and their endogenous
creatinine clearance were greater than 70 ml/min/1.73 m2. Simi-
larly, the disease controls had normal renal function and the study
was performed prior to the commencement of any corticosteroid
or cytotoxic treatment.
The study, which conformed to the Declaration of Helsinki, was
approved by the ethical subcommittee of the hospital involved.
Informed written consent was obtained from all subjects.
Isolation of CD4+ cell subset
Peripheral blood mononuclear cells (PBMC) separated by
Isopaque-Ficoll (Lymphoprep, Nycomed AS, Oslo, Norway) den-
sity gradient centrifugation were washed with phosphate buffered
saline (PBS), and then resuspended in culture medium consisting
of RPM! 1640 (Gibco, Chargrin Falls, New York, USA) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS;
Gibco), L-glutamine (2 mM), penicillin (100 U/mI), and strepto-
mycin (100 ig/ml). Magnetizable polystyrene beads coated with
MoAb specific for CD4 (Dynal AS, Oslo, Norway) were used to
select CD4+ T cells from PBMC as described previously [8]. The
purity for CD4+ T cells was found to be greater than 99.8% by
flow cytometry. Cell viability was greater than 98% as determined
by Trypan blue dye exclusion test.
Culture of CD4+ cells
Isolated CD4+ cells, adjusted to 1 ml aliquots of 1 >< 106 cells,
were dispended into 48-well culture plates. The cells were incu-
bated at 37°C for six hours in humidified atmosphere with CO2 in
the presence of phytohemagglutinin (10 g/ml) and phorbol
myristate acetate (0.5 ng/ml). Preliminary experiments indicated
that these concentrations induce maximal cytokine production
with lowest toxicity [9, 10]. Only a very low amount of TGF-13
mRNA was detected in unstimulated cells, whereas 13-actin and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA
were readily detected in unstimulated cells [8].
Preparation of total RNA
A microadaptation of the guanidinium thiocyanate/cesium
chloride procedure was used to prepare total RNA from CD4+
cells. All RNA samples prepared from 1 x 106 cells were
dissolved in 20 1.d DEPC-dH2O and were stored at —70°C until
assay. The quality of RNA was checked by formaldehyde agarose
gel electrophoresis and 2 1 of total RNA contained approxi-
mately 0.1 g RNA.
Oligonucleotide primers
Specific primers of TGF-13, 13-actin, and GAPDH were obtained
from Clontech (Palo Alto, California, USA). The primer sequences
for TGF-p are 5'GCCGFGGACACCAACTATFGCT and AG-
GCFCCAAATGTAGGGGCAGG3'. The primer sequences for
f3-actin are 5'ATGGATGATGATATCGCCGCG and CrAGAA-
GCATTTGCGGTGGACGATGGAGGGGCC3' and those of
GAPDH are 5'TGAAGGTCGGAGTCAACGGATTFGGT and
CATGTGGGCCATGAGGTCCACCAC3'.
Detection of cytokine gene expression by PCR
The gene expression was studied in CD4+ cells using the
GeneAmp RNA PCR kit (Perkin Elmer Cetus, Norwalk, Con-
necticut, USA). mRNAs of each sample were first reverse tran-
scribed into cDNAs, which in turn were subjected to PCR
amplification using specific primers for individual cytokine. In
brief, first-strand DNA was synthesized in a final volume of 20 d
with the following components: 2 p1 total RNA in DEPC-dH2O,
2.5 mM Oligo d(T) 16 primers, 5 mtvi MgCI2, 10 nM Tris-HC1
buffer, pH 8.3, 50 mrvi KCI, 1 mivi dNTP, and 10 U of RNase
inhibitor. The mixture was incubated in a Perkin-Elmer Cetus
DNA Thermal Cycler at 42°C for 30 minutes followed by five
minutes at 99°C and flash cooling to 4°C. PCR was performed
using GeneAmp PCR system (Perkin Elmer, Cetus). cDNA
(10 tl) was mixed with 2 mivi MgCl2, 10 mivi Tris-HCI buffer, 50
mM KC1, 0.05 LM specific TGF-p PCR primers, 0.1 LM /3-actin
primer, 1.25 U AmpliTaq DNA polymerase, and 2 1.tCi[cr-32P]-
dCTP in a final volume of 50 p1. Amplification was started with
two minutes of denaturation at 94°C followed by 30 PCR cycles.
Each cycle consisted of 60 seconds at 94°C for denaturation, 60
seconds at 62°C for annealing, and one minute at 72°C for
extension. The final extension lasted 10 minutes at 72°C in all
instances. The experimental condition and number of cycles of
PCR were predetermined to ensure the amount of cytokine and
"housekeeping" gene fragments were in the linear range of
amplification. The efficiency of cDNA was controlled by using
control cRNA (IL-la RNA from plasmid pAW1O9 provided by
Clontech) in every reaction.
Negative controls for PCR consisted of: (i) samples in which the
reverse transcriptase was omitted to detect any contamination by
genomic cDNA; and (ii) reagents control in which RNA was
replaced by DEPC-dH2O. Positive control DNAs for each cyto-
kine were obtained from Clontech Laboratory.
Vertifi cation of "housekeeping" gene
/3-actin has been used as a constitutively expressed "housekeep-
ing" gene in PCR but in very rare occasions, isolated studies
reported that its expression may be changed in disease states [11,
12]. Random RNA samples from each group of subjects (17
patients with IgA nephropathy and 19 healthy controls) were
studied comparing the gene expression of /3-actin with that of
another endogenous sequence, GAPDH in order to detect any
obvious change of /3-actin gene expression in IgA nephropathy.
Agarose gel electrophoresis and semiquantitation of PCR products
The PCR mixture (20 p1) was added to 5 p1 of loading dye mix
and electrophoresed in a 90 V constant-voltage field in 1.7%
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agarose (Sigma, St. Louis, Missouri, USA) containing ethidium
bromide until the bromophenol blue dye front had migrated for a
distance of 6 cm. qX174/HaeIII digested DNA (Gibco) was used
to determined the size of the PCR products. After electrophore-
sis, gel slides corresponding to the radioactive bands of PCR
product were excised and counted by liquid scintillation. 32P
incorporated into the PCR products of respective cytokines was
normalized with that of 13-actin PCR products as described
previously [8]. The results were expressed as a ratio calculated
from the counts/mm of amplified cytokine gene product over the
counts/mm of amplified /3-actin PCR product.
Immunochemistiy of renal biopsies
Indirect immunofluorescence was performed with standard
method as previously described [13]. Sections of 4 im cut from
frozen tissues were incubated with the primary monoclonal anti-
body (1:20 dilution) (1835-01, Genzyme, Cambridge, Massachu-
setts, USA), then overlaid with the appropriate secondary anti-
body (1:20 dilution) [rabbit anti-mouse IgG, F(ab')2 fragments,
Sigma] labeled with fluorescein in the conventional manner. The
monoclonal antibody specifically recognized human TGF-f31 and
TGF-p2. The immunofluorescence staining was scored blindly
without clinical or histopathologic details into —,
—1+, ++, or
+ + +. Control sections were overlaid with nonimmune mouse
serum as the primary antibody, or with secondary antibody alone.
These controls were negative.
Statistics
Because the distribution of the cytokine gene expression (ex-
pressed as a ratio of TGF-f3 mRNAJj3-actin mRNA) appeared not
to be normal, group results were expressed as median and range
unless stated otherwise and non-parametric tests for significance
were performed. The levels of the TGF-13 gene expression be-
tween the patients and controls and the comparison of the TGF-3
gene expression between three groups of IgA nephritic patients
were analyzed using the Wilcoxon rank sum test. As three
separate comparisons of TGF-p gene expression were made, the
Bonferonni correction was applied, and statistical significance was
determined to be P < 0.017. For analysis of mesangial TGF-p
staining and glomerular sclerosis, chi-square test was used and the
statistical significance was determined to be P < 0.05.
Results
Plasma IgA levels
The three groups of subjects were comparable with age, sex
ratio, and their creatinine clearances were greater than 70 mI/mini
1.73 m2. Nevertheless, the plasma IgA levels in patients with IgAN
(3.41 glliter, range 1.88 to 5.37) were significantly higher than that
of healthy controls (2.10 glliter, range 1.33 to 2.89, P < 0.001) or
that of MCN/FGN (2.25 g/liter, range 1.21 to 2.54, P < 0.001).
Reverse transcription-polymerase chain reaction (RT-PCR)
Preliminary studies were performed to optimize the RT-PCR
condition for amplification of cytokine and /3-actin mRNAs [8].
The size of the PCR products was confirmed by agarose gel
electrophoresis (Fig. 1). The magnesium ion concentration,
primer concentration and the number of cycles used for amplifi-
cation were adjusted to ensure that the PCR products were
analyzed before the copies of PCR products reached saturation.
Fig. 1. Demonstration of amplified TGF-13 mRWA reverse transcription
(RT)-polymerase chain reaction (PCR) products by agarose gel electrophore-
sis. Lane (M) represents molecular weight marker, 4X174 RF DNA
HaeIII Digest. Lane 1 represents RNA from CD4+ lymphocyte without
phytohemagglutinin (PHA) and phorbol myristate acetate (PMA) stimu-
lation. Only amplified $3-actin mRNA (1128 bp) was detected in unstimu-
lated CD4+ lymphocytes. Lane 2 represents RNA from CD4+ lympho-
cyte stimulated with PHA-PMA for 6 hours. TGF-f3 mRNA (161 bp) was
only detectable after PHA-PMA stimulation. Lane 3 represents PCR
product (omitting RT) of RNA from CD4+ lymphocyte stimulated with
PHA-PMA for 6 hours. Neither p-actin nor TGF-13 mRNA was detected.
Lane 4 represents PCR product from negative control.
The efficiency of transcription of RNA was confirmed by using
control cRNA in every reaction. The difference in RNA isolation
and eDNA synthesis was normalized using a housekeeping gene,
f3-actin. Most RNA samples had RT-PCR at the same time or on
the same day to avoid interbatch variation or imprecision. If
amplifications were done in separate time, random patient sam-
ples/control samples were repeated to check for variation. Data
showed that RT-PCR at different time gave similar efficiency and
similar results. The measurement was highly reproducible and the
coefficient of variation was shown to be 6.2%.
In order to detect any change of 13-actin gene expression in
CD4+ T cells in IgA nephropathy, the ratio of GAPDH to 13-actin
was studied in random RNA samples from 17 patients with IgA
nephropathy and 19 healthy controls. No significant difference
was demonstrated (0.51, range 0.23 to 0.78 for IgAN vs. 0.49,
range 0.25 to 0.81 for controls, P = 0.56) indirectly suggesting that
there is no obvious change in 13-actin gene expression in CD4+ T
cells related to this nephropathy.
Cytokine mRNA levels in CD4+ cells
The cytokine mRNA levels in CD4+ cells expressed as a ratio
of TGF-f3 mRNAJj3-actin mRNA are shown in Figure 2. The
TGF-J3 gene expression in circulating CD4+ cells isolated from
patients with IgAN during clinical quiescence (1.10, range 0.24 to
3.87) was significantly higher than that of healthy controls (0.88,
range 0.20 to 3.83, P = 0.0157) or patients with MCN/FGN (0.36,
range 0.09 to 1.60, P = 0.006).
When the patients with IgAN were stratified according to the
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Fig. 2. Transcription of mRNA for TGF-f3 in CD4+ T cells following
activation by PHA-PM'l. The CD4+ T cells purified from patients with
IgAN (N = 31) expressed more TGF-p mRNA per cell than those from
healthy controls (N = 25) or patients with MCNIFGN (N = 10). Values(in semi-logarithm scale), expressed as the ratio of TGF-13 mRNA and
13-actin mRNA, were compared by Wilcoxon rank sum test with the
Bonferonni correction, and statistical significance was determined to be
P < 0.017. Bars indicate median values.
severity of their glomerular and interstitial lesions, there was an
apparent increase in expression of TGF-13 gene in CD4+ T cells
associated with increased histopathologic grading despite the
plasma samples being collected during clinical quiescence (Fig. 3).
Patients with Grade 3 pathologic findings showed significantly
higher TGF-f3 gene expression in their CD4+ cells (2.17, range
1.45 to 3.87) when compared with patients with Grade 1 (0.52,
range 0.24 to 0.79) or Grade 2 histopathologic findings (1.2, range
0.5 to 3.33; P = 0.0006 and = 0.0066, respectively). Similarly, the
TGF-13 gene expression in CD4+ cells from IgA nephritic patients
with Grade 1 histopathologic changes was significantly lower than
that of patients with Grade 2 histopathologic findings (P
0.0019).
Correlation between the mesangial deposition of TGF-f3 and the
histopathologic changes
Light microscopy revealed no mesangial hypertrophy or sclero-
sis in the renal biopsies from the 10 patients with MCN or FGN.
Immunoreactivity of anti-TGF-/3 was negative or trace in the
glomerular mesangium of kidney biopsies from healthy controls
who died of traumatic accident or in kidney biopsies from the ten
disease controls. However, the immunostaining for TGF-f3 was
prominent in the expanded mesangium of some patients with IgA
nephropathy and the pattern was similar to that of IgA (Fig. 4).
There was significant correlation (P < 0.05) between the mesang-
ial staining of TGF-j3 and the severity of histopathologic grading
according to glomerular and interstitial sclerosis (Table 1).
Discussion
Transforming growth factor-13, a 28 kD homodimer produced
by virtually all cell types, has potent regulatory effects on inflam-
mation, the immune response, and extracellular matrix produc-
tion [14]. Fibrosis is commonly preceded by inflammatory changes
with varying degrees of immune response and in the late stages is
IgAN IgAN IgAN
stage 1 stage 2 stage 3
Fig. 3. Transcription of mRNA for TGF-13 in CD4+ T cells following
activation by PHA-PMA. In stage 1 N = 13, stage 2 N = 12, and stage 3N = 6. The increase in TGF-3 mRNA per CD4+ T cell correlated
significantly with the severity of the histopathologic grading of IgA
nephropathy. Values (in semi-logarithm scale), expressed as the ratio of
TGF-/3 mRNA and 13-actin mRNA, were compared by Wilcoxon rank sum
test with the Bonferonni correction, and statistical significance was
determined to be P < 0.017. Bars indicate median values.
typified by increased deposition of extracellular matrix and an
increased number of fibroblasts. Recent studies of fibrosis in the
kidney, liver, and lung have provided convincing evidence that this
cytokine, TGF-/3, is critical for full expression of fibrotic response
[6, 15—171.
Mature TGF-f3 is present in the normal glomerulus in both the
glomerular basement membrane and glomerular cells. Flanders
and coworkers [18] suggested that extracellular TGF-13 was bound
to matrix proteins. The progressive accumulation of extracellular
matrix in the glomerulus that include normal constituents (type
IV and V collagen and laminin) and abnormal constituents (type
I and III collagen), occurs in different types of glomerulonephrit-
ides, including mesangial proliferative glomerulonephritis, focal
glomerulosclerosis, and diabetic nephropathy [19—21]. A causal
role of TGF-f3 is strongly suggested by the elevated expression
TGF-13, and it is associated with increased synthesis of collagen,
proteoglycans, and fibronectin in experimental models of mesang-
ial proliferative glomerulonephritis [22], anti-glomerular base-
ment membrane nephritis [15], and focal glomerulosclerosis [23].
Furthermore, systemic treatment with antagonists of TGF-13 in
animals that were induced to develop experimental mesangial
proliferative glomerulonephritis prevented the development of
glomerular sclerosis [6].
IgA nephropathy [IgAN] is the most common glomerulonephri-
tis worldwide [1], and some recent studies of the natural history of
large relatively nonselected cohorts of patients by life-table anal-
ysis reveal 10-year renal survival ranges between 80 and 87% in
adult patients [24]. The pathology is characterized by a mesangial
proliferative glomerulonephritis, and both glomerular and inter-
stitial fibrosis/sclerosis are important prognostic factors in the
subsequent development of renal impairment [4, 5]. The presence
of TGF-p in glomerular mesangium of kidney biopsies from 35
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Fig. 4. Immunofluorescent microscopy of kidney sections from patients with IgA nephropathy stained with monoclonal antibody to IgA or TGF-131 and
TGF-j32. (a) mesangial staining of IgA, (b) mesangial staining of TGF-f31 and TUF-32 with score of +, (c) mesangial staining of TUF-fJl and TUF-f32
with score of + +, and (d) mcsangial staining of TGF-j31 and TGF-/32 with score of + + +. The mesangial distribution of IgA and TGF-j3 were similar.
Magnification x 400.
Table 1. Correlation between the immunofluorescence staining of
transforming growth factor-p in glomerular mesangium and the
histopathologic grading in patients with IgA nephropathy
N
Immunoreactive TGF-3
—/+to+ ++ +++
Stagel 13 8 4 1
Stage2 12 2 7 3
Stage3 6 1 3 2
The number (N) represents the number of patients. Chi-square test =
7.088, P < 0.05.
patients with mesangial proliferative glomerulonephritis (includ-
ing 24 patients with IgA nephropathy) was only recently demon-
strated by Yoshioka and coworkers [25] using indirect immuno-
fluorescence with polyclonal antibodies. Staining intensity,
compared with normal tissues, was generally higher and there was
apparent correlation between mesangial staining for the small
latent form of TGF-/31 and the mesangial matrix increase. In situ
hybridization revealed TUE-/fl mRNA expression in both gb-
merular cells and infiltrating monocyte-macrophages in these
kidney biopsies, although increased TUF-pl mRNA expression
was more prominent with the former [25].
In the present study, we further extend the observation by
Yoshioka and coworkers [25] using indirect immunofluorescence
with monoclonal instead of polycbonal antibodies, and we specif-
ically examined IgA nephropathy rather than mesangial prolifer-
ative glomerulonephritides that include various distinct patho-
logic entities. Whereas Yoshioka and coworkers [23] had shown a
closed association between the immunofluorescent reactivity of
anti-TGF-/31 and the increase in mesangial matrix in their patients
with mesangial proliferative glomerulonephritis, we observed a
significant correlation between the mesangial staining of TUE-/il
and TGF-/32 and the severity of histopathobogic grading according
to glomerular and interstitial sclerosis in our patients with IgA
nephropathy. Although trace amounts of TUF- can occasionally
be detected in normal glomeruli or renal biopsies in minimal
change nephropathy, the predominant deposition of TGF-/3 in the
kidney biopsies in patients reported by Yoshioka and coworkers
[251 and in our patients that correlated with the histopathologic
severity provided strong evidence supporting the notion that
TUE-p increases the synthesis of collagen, proteoglycans, and
fibronectin leading to gbomerular sclerosis. It is most intriguing to
note a recent study by Naka et al [26] on 14 Japanese patients with
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IgAN, which reported a strong message of TGF-/3 mRNA in
glomerular mesangial cells and interstitial infiltrating cells only in
those cases with severe tissue damage. These findings suggest the
observed phenomenon of TGF-13 deposition associated with his-
topathologic sclerosis is likely to be universal and is not confined
to the genetic cohort of Chinese.
Despite increased immunoreactivity to TGF-!31 and TGF-132
that was detected in glomerular cells in IgA nephropathy, it
remains uncertain whether the mesangial TGF-13 deposits reflect
TGF-/3 produced by the mesangial cells alone or from additional
sources elsewhere in the body (including circulating and infiltrat-
ing T cells and macrophages) and being filtered by the glomeruli.
If TGF-/3 from the "non-glomerular" sources were contributory to
the accumulation of mesangial matrix after filtering by the gb-
meruli, then the systemic treatment with antagonists of TGF-f3
may potentially alleviate the pathologic changes. Border and
coworkers [6] had demonstrated the prevention of the develop-
ment of glomerular sclerosis in an animal model of mesangial
proliferative glomerulonephritis by intravenous administration of
antagonist to TGF-/3. Another factor that supports a potential
role of TGF-/3 from circulating and infiltrating T cells or macro-
phages in enhancing mesangial matrix formation is the huge
number of T cells and macrophages compared with mesangial
cells. Hence, it will be interesting to examine the TGF-p released
by CD4+ T cells from patients with IgA nephropathy.
We examined the gene expression of TGF-/3 in purified CD4+
T cells by PCR following reverse transcription using /3-actin as a
housekeeping gene. The reference mRNA and the target mRNA
were processed together for the entire duration of the experiment.
This technique gives a semiquantitative estimate of the number of
copies of mRNA per cell, but not the proportion of cells within
the sample that transcribe cytokine genes. Our technique is likely
to be less ideal than the competitor PCR which has been
described recently [27] although both techniques share the poten-
tial problem of the efficiency of the reverse transcription. Never-
theless, accuracy and reproducibility were checked and control
cRNA was used in every reaction. The rare possibility that the
gene expression of f3-actin be altered in this form of nephritis is
not supported by the comparison between the gene expression of
/3-actin with another reference mRNA, GAPDH, TGF-/3 mRNA
was measured in stimulated CD4+ T cells because the amount of
TGF-p mRNA in unstimulated T cells from normal subjects is
small [8, 28] and is often not detectable in unstimulated T cells
from patients with IgAN [29]. Since increased T cell activation
and cytokine release are observed during acute exacerbation of
IgAN [30, 31], CD4+ T cells were only prepared from patients in
clinical quiescence in order to assess the intrinsic hyperactivity of
T lymphocyte in IgAN. We demonstrated an increase of TGF-p
mRNA expression by mitogen activated CD4+ T cells from
patients with IgAN. Furthermore, the levels of TGF-/3 mRNA
expression correlated significantly with the severity of glomerular
and interstitial pathology. These findings tend to support our
speculation that, in addition to TGF-13 produced de novo by the
mesangium, TGF-p from systemic sources can also contribute to
mesangial proliferation by binding to the mesangial cells after
being filtered by the kidney.
In conclusion, we have demonstrated that there is increased
TGF-13 gene expression in CD4+ T cells from patients with IgA
nephropathy that may enhance the mesangial proliferation and
glomerular sclerosis in this disease entity.
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